Respiratory devices include CPAP/BiPAP for sleep apnea (ResMed, Philips), home oxygen concentrators, ventilators, nebulizers, inhaler delivery devices, and emerging implantable phrenic-nerve stimulators for central sleep apnea. Products include ventilators, CPAP devices, oxygen concentrators, nebulizers and spirometers. Post-market safety issues, such as foam degradation recalls, have shaped FDA oversight. Durable medical equipment rules govern US payment for home devices.

Why it matters

Philips Respironics recall (2021–2024) reshaped the CPAP market. Connected CPAP data (myAir, AirView) drives adherence and payer reauthorization.

Common pitfalls

•Failing to identify all applicable classifications and regulatory pathways for a respiratory device across different markets can lead to significant delays.
•Underestimating the cybersecurity risks associated with connected respiratory devices, particularly those transmitting patient data, is a common pitfall.
•Not adequately addressing usability and human factors engineering during the design and development of respiratory devices can result in patient harm or misuse.
•Overlooking post-market surveillance requirements for respiratory devices, especially in light of widespread recalls, can lead to enforcement actions and reputational damage.
•Incorrectly assuming that software components of a respiratory device do not require separate regulatory consideration is a mistake quality professionals make.

Sources

American Thoracic Society · ATS
MedTech Europe - Facts & Figures · MedTech Europe
MedTech Dive · MedTech Dive
Respiratory devices · U.S. Food and Drug Administration (FDA)

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.